In addition, the treatment with antidiabetic agents, including glucagon-like peptide-1 (GLP-1) receptor agonists, exendin-4, and liraglutide, which are approved for the treatment of T2DM, has been shown to facilitate insulin signaling and sequential reductions in the endogenous levels of Aβ in the brain and prevent hippocampal neuronal death [80]. Here, INS is linked to type 2 diabetes mellitus.